About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The search for quality and innovation has always been an inherent part of the activity of the Stroke Research Group and represents the common thread that leads us to excellence and continuous improvement.
In recent years, the Stroke Research Group has established itself as a leader in the management, recruitment and international coordination of multicenter clinical trials, as well as in the development of patents for new thrombectomy devices and the creation of new technological solutions and digital platforms to improve the diagnosis, treatment and follow-up of stroke patients. Robust strategic alliances have also been consolidated with public and private entities that ensure the viability and scalability of the research projects initiated in our group.
The Stroke Research Group is made up of a transversal and multidisciplinary team that shares a common idea: to contribute from its area of knowledge to the care and management of stroke through the effective transfer of knowledge and the complementarity of the processes of clinical research.
IP: Marta Aurora Rubiera Del Fueyo Collaborators: Maria Victoria Sala Sanz de Madrid, Cristina Guirao Martinez, Claudia Meza Burgos, Federica Rizzo, Ester Sanchez Gavilan, David Rodriguez Luna, Renato Simonetti Funding agency: EUROPEAN COMMISSION Funding: 567950 Reference: VALIDATE_HE-HLTH-DISEASE21 Duration: 01/05/2022 - 30/04/2026
IP: Carlos Molina Cateriano Collaborators: Noelia Rodríguez Villatoro, Juega Mariño, Jesus Maria, Federica Rizzo, David Rodriguez Luna, Carole Conforti, Renato Simonetti Funding agency: EUROPEAN COMMISSION Funding: 396730 Reference: RES-Q PLUS_HE-HLTH-TOOL21 Duration: 01/11/2022 - 31/10/2026
IP: Anna Santamaria Margalef Collaborators: Joan Morote Robles, Olga Méndez Fernández, Borja Martínez Vizuete, Giorgio Colangelo, Olga Méndez Fernández, Olga Méndez Fernández, Olga Méndez Fernández Funding agency: Ministerio de Asuntos Económicos y Transf Digital Funding: 703098.75 Reference: MIA.2021.M02.0005_SANTAMARIA Duration: 01/10/2021 - 31/12/2024
PMID: 37919456 Journal: BONE MARROW TRANSPLANTATION Year: 2023 Reference: Bone Marrow Transplant. 2023 Nov 2. doi: 10.1038/s41409-023-02114-0. Impact factor: Publication type: Paper in international publication Authors: Albert, Eliseo; Amat, Paula; Balaguer, Aitana; Barba, Pere; Beas, Francisco; Benzaquen, Ana; Bhuva, Parita; Bonafe, Alain; Budzik, Ronald F; Campos, Diana et al. DOI: 10.1038/s41409-023-02114-0
PMID: 37919201 Journal: Enfermedades infecciosas y microbiologia clinica ( Year: 2023 Reference: Enferm Infecc Microbiol Clin (Engl Ed). 2023 Oct 31:S2529-993X(23)00255-1. doi: 10.1016/j.eimce.2023.07.007. Impact factor: Publication type: Clinical guide Authors: Albucher, Jean Francois; Ariza, Javier; Baeza, Jose; Belzunegui-Otano, Joaquin; Benito, Natividad; Buetikofer, Lukas; Cobo, Javier; Del-Toro, Maria-Dolores; Dobrocky, Tomas; Eker, Omer et al. DOI: 10.1016/j.eimce.2023.07.007
PMID: 37932449 Journal: Clinical Neuroradiology Year: 2023 Reference: Clin Neuroradiol. 2023 Nov 6. doi: 10.1007/s00062-023-01354-3. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Almenar-Bonet, Luis; Andersson, Tommy; Atienza, Felipe; Aurelio Sarralde-Aguayo, Jose; Baguda, Javier De Juan; Barge-Caballero, Eduardo; Blasco-Peiro, Teresa; Camino, Manuela; Carlos Sanchez-Salado, Jose; Coll, Elisabeth et al. DOI: 10.1007/s00062-023-01354-3
PMID: 37935260 Journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Year: 2023 Reference: J Allergy Clin Immunol. 2023 Nov 5:S0091-6749(23)01390-8. doi: 10.1016/j.jaci.2023.10.018. Impact factor: Publication type: Paper in international publication Authors: Albert, Michael H; Andersson, Tommy; Aumann, Volker; Bakhtiar, Shahrzad; Barlogis, Vincent; Booth, Claire; Buddingh, Emmeline P; Cagdas, Deniz; Castelle, Martin; Chan, Alice Y et al. DOI: 10.1016/j.jaci.2023.10.018
The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.
Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.
The award is a recognition for his significant contribution to the development of research in multiple sclerosis within the Catalan Institute of Health.
